



Analysis of longitudinal diffusion-weighted images in healthy and pathological aging: An ADNI study



Frithjof Kruggel^{a,*}, Fumitaro Masaki^a,
Ana Solodkin^b, for the Alzheimer's Disease Neuroimaging Initiative


^a Department of Biomedical Engineering, University of California, Irvine, USA

^b Department of Anatomy & Neurobiology and Neurology, University of California, Irvine, USA

HIGHLIGHTS

- Voxel-based morphometry is extended to analyze longitudinal images via a mixed-effects model.
- This method is applied to distinguish healthy and pathological aging in the brain's white matter.
- A parameter at the single subject level describes individual differences associated with aging.
- A classifier discriminates patients with Alzheimer's disease with a predictive power of 0.99.
- This model provides a promising biomarker predicting the risk of conversion to Alzheimer's disease.

GRAPHICAL ABSTRACT



Diffusion-weighted MR imaging provides promising parameters that are suggestive of a biomarker for the early detection of Alzheimer's Disease. Highly discriminative white matter fiber structures belong to the hippocampus and parahippocampus, e.g., the alveus and perforant path.

ARTICLE INFO

Article history:

Received 25 July 2016

Received in revised form 28 October 2016

Accepted 30 December 2016

Available online 3 January 2017

Keywords:

Voxel-based morphometry
Linear mixed-effects modeling
Aging
Biomarker
Longitudinal imaging
Alzheimer's disease

ABSTRACT

Background & new method: The widely used framework of voxel-based morphometry for analyzing neuroimages is extended here to model longitudinal imaging data by exchanging the linear model with a linear mixed-effects model. The new approach is employed for analyzing a large longitudinal sample of 756 diffusion-weighted images acquired in 177 subjects of the Alzheimer's Disease Neuroimaging initiative (ADNI).

Results and comparison with existing methods: While sample- and group-level results from both approaches are equivalent, the mixed-effect model yields information at the single subject level. Interestingly, the neurobiological relevance of the relevant parameter at the individual level describes specific differences associated with aging. In addition, our approach highlights white matter areas that reliably discriminate between patients with Alzheimer's disease and healthy controls with a predictive power of 0.99 and include the hippocampal alveus, the para-hippocampal white matter, the white matter of the posterior cingulate, and optic tracts. In this context, notably the classifier includes a sub-population of patients with minimal cognitive impairment into the pathological domain.

Conclusion: Our classifier offers promising features for an accessible biomarker that predicts the risk of conversion to Alzheimer's disease.

* Correspondence to: 202 Rockwell Engineering Center, University of California, Irvine, CA 92697-2755, USA.
E-mail address: fkruggel@uci.edu (F. Kruggel).

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Significance statement

This study assesses neuro-degenerative processes in the brain's white matter as revealed by diffusion-weighted imaging, in order to discriminate healthy from pathological aging in a large sample of elderly subjects. The analysis of time-series examinations in a linear mixed effects model allowed the discrimination of population-based aging processes from individual determinants. We demonstrate that a simple classifier based on white matter imaging data is able to predict the conversion to Alzheimer's disease with a high predictive power

© 2017 Elsevier B.V. All rights reserved.

1. Introduction

A vast amount of imaging methods (Braskie et al., 2013) and image-derived metrics (Weiner et al., 2012) have been proposed for the non-invasive, early detection of Alzheimer's diseases (AD) (McKhann et al., 2011). Because AD was primarily assessed via grey matter (GM) degeneration, an initial focus was given on the quantification of GM regions and their metabolic activity. While it is possible to describe the disease process quantitatively in large population samples, detecting correlates of the relative minute brain degeneration in early stages of AD is difficult to achieve at the individual level, due to the limited test-retest precision of current imaging devices and analysis processes. In search of accessible biomarkers for AD that precede a macroscopically measurable brain atrophy, amyloid PET imaging using a [¹¹C] PIB marker (Morris et al., 2009), levels of specific proteins in the cerebro-spinal fluid (CSF) (Villain et al., 2010), and more recently, levels of specific phospholipids in plasma (Mapstone et al., 2014) have so far the best predictive power. Different analytic strategies based on machine learning procedures were developed that use combinations of cortical markers and protein measures for an automatic discrimination of AD patients and controls (e.g., Gao et al., 2015; Liu et al., 2013; Suk and Shen, 2014; Yu et al., 2016; Zu et al., 2015), with correct classification rates up to 96.5%.

Diffusion-weighted MR imaging (DWI) examines microstructural properties of white matter (WM). It is well established that the structural integrity of axons and their structural matrix is affected by this degenerative process long before neuronal loss (Hyman et al., 1986; Sadun and Brassi, 1990; Scheltens et al., 1995; Solodkin et al., 2013). There is a rich literature on DWI in healthy and pathological aging (for reviews see Chua et al., 2008; Madden et al., 2012; Sullivan and Pfefferbaum, 2006, 2007) where cognitively normal elderly subjects with positive amyloid beta protein levels were found to have abnormal diffusion metrics (Molinuevo et al., 2014). Converging evidence is documented that metrics based on DWI have high sensitivity for detecting AD-related WM changes (Amlie and Fjell, 2014; Bennett et al., 2010; Douaud et al., 2011; Huang et al., 2012; Kantarci et al., 2005; Keihaninejad et al., 2013; Salat et al., 2010; Teipel et al., 2010, 2014; Wang et al., 2016). In this work, we investigate whether DWI-based metrics are capable biomarkers that provide sufficient power to predict conversion to AD (Douaud et al., 2013; Solodkin et al., 2013) and allow an individual risk assessment. We employ data from a longitudinal study, in order to distinguish between the dynamics of aging- and disease-related influences on WM properties. More specifically, we analyze structural and diffusion-weighted imaging data in a sample of 177 elderly subjects with 2–6 longitudinal examinations collected in the ADNI Go and ADNI 2 studies (ADNI General Procedure Manual, 2016) over a period between 3 months to 4 years.

Most current studies in time-series analysis of DWI data have employed "tract-based statistics" to extract image metrics in region-of-interests (ROIs) for further statistical analysis (e.g., Nir et al., 2015; Zhan et al., 2015). While such a two-level strategy offers the advantage of abstracting from large data sets in an early processing stage, there is a risk of missing valuable detail due to the focus on a subset of the cerebral WM. Instead, we use voxel-based morphometry (VBM), a widely used framework to assess neuroimaging data in relation to demographic and clinical features of population samples (Ashburner and Friston, 2000). We replace the linear model (LM) in VBM by a linear mixed-effects model (LMM), so that single subject-related effects assessed in repeated measurements can explicitly be modeled. In this single-level strategy, we retain the full, voxel-based information in the statistical analysis. Due to the large sample included, we achieve a high statistical power that allows drawing conclusions not only for the WM compartment (as in tract-based statistics), but for GM and composite GM/WM regions as well. Linear mixed-effects models have been a method of choice for the exploratory analysis of data acquired in longitudinal studies (Galecki and Burzykowsli, 2013; Laird et al., 1987; Lindstrom and Bates, 1988). We (Kruggel et al., 2010) and others (e.g., Beckmann et al., 2003; Bernal-Rusiel et al., 2013; Driscoll et al., 2009; Resnick et al., 2003; Schumann et al., 2010) have used mixed-effects modeling to assess longitudinal imaging data, based on quantitative features extracted from images rather than directly on voxel-wise data.

In the following section, we formally introduce the image-based measures, the linear mixed-effects models, and describe the study sample and image processing steps. Second, we discuss (a) age- and disease-related influences on WM integrity, (b) demonstrate the advantage of using subject-level information provided by LMM, and (c) show that static and time-dependent measures can be combined to assess the individual risk of converting to Alzheimer's disease (AD). The final section is devoted to an in-depth discussion of the advantages of LMM, the neuro-biological results obtained, and the potential of an image-based biomarker for the early detection of Alzheimer's disease.

2. Materials and methods

Briefly, we characterize voxel-wise diffusive properties by computing diffusion tensors and their scalar parameters fractional anisotropy (FA), medial and radial diffusivity (MD, RD), in addition to the T₂ intensity (T2) as obtained from the gradient-free image. Then, we use the context of voxel-based morphometry to evaluate the dependency of imaging data on clinical and demographical data, but replace the linear model with a linear-mixed effects model to explicitly model subject-wise longitudinal data. The mixed effects model can be understood as an extension of linear

regression, where observations are grouped into units, and sample-wide (fixed) effects are separated from unit-wise (random) effects. In this context, a unit corresponds to the longitudinal data acquired in a single subject. Thus, LMEM allows differentiating between sample-level and subject-level effects.

2.1. Image-based measures

Diffusion-weighted MR imaging assesses the direction-dependent diffusion of protons. More specifically, the mobility of extra- and intracellular water molecules hindered by membranes, such as axonal sheaths is examined. The signal $S(\mathbf{g})$ weighted in gradient direction \mathbf{g} is related to the un-weighted signal S_0 by the Stejskal-Tanner equation:

$$\frac{S(\mathbf{g})}{S_0} = \exp(-\mathbf{b}\mathbf{g}^T \mathbf{D}\mathbf{g}), \quad \mathbf{D} = \begin{pmatrix} d_{xx} & d_{xy} & d_{xz} \\ d_{xy} & d_{yy} & d_{yz} \\ d_{xz} & d_{yz} & d_{zz} \end{pmatrix}$$

where the symmetric, positive semi-definite matrix \mathbf{D} captures the voxel-wise anisotropy of water diffusion, and other measurement-related parameters are collected in b. Most commonly, the matrix \mathbf{D} is decomposed into its three eigenvectors ($\mathbf{e}_1, \mathbf{e}_2, \mathbf{e}_3$), corresponding to the main directions of water motion, and its three eigenvalues ($\lambda_1, \lambda_2, \lambda_3$), representing the amount of diffusion in each direction. Voxel-wise diffusive properties are often expressed by scalar measures fractional anisotropy (FA), mean diffusivity (MD) and radial diffusivity (RD):

$$FA = \sqrt{\frac{3((\lambda_1 - \bar{\lambda}_1)^2 + (\lambda_2 - \bar{\lambda}_2)^2 + (\lambda_3 - \bar{\lambda}_3)^2)}{2(\lambda_1^2 + \lambda_2^2 + \lambda_3^2)}}$$

$$MD = \frac{1}{3}(\lambda_1 + \lambda_2 + \lambda_3),$$

$$RD = \frac{1}{2}(\lambda_2 + \lambda_3)$$

Higher FA values indicate a larger anisotropy, typically found in intact “unidirectional” fiber bundles. Higher MD values correspond to a larger overall mobility of water, often related to a higher fraction of extra-cellular water. RD characterizes the amount of diffusion radial to a fiber bundle, with higher values indicating a lower fiber integrity (“leakiness”). Note that voxels with more than one fiber compartment are expected to have a lower FA (i.e., multiple fiber directions) and a higher MD (i.e., a larger fraction of extracellular space). As an additional, independent indicator of WM degeneration, we included the signal of the T2-weighted images in our analysis, which is roughly proportional to the fraction of extracellular water.

2.2. The linear mixed-effects model

The general form of the linear mixed effects model is written as (Laird et al., 1987):

$$\mathbf{y} = \mathbf{X}\boldsymbol{\beta} + \mathbf{U}\boldsymbol{\gamma} + \boldsymbol{\epsilon}, \quad \left(\begin{matrix} \boldsymbol{\gamma} \\ \boldsymbol{\epsilon} \end{matrix} \right) \sim N_{mq+n} \left(\left(\begin{matrix} \mathbf{0} \\ \mathbf{0} \end{matrix} \right), \left(\begin{matrix} \mathbf{G}(\boldsymbol{\theta}) & \mathbf{0}_{mq \times n} \\ \mathbf{0}_{n \times mq} & \mathbf{R}(\boldsymbol{\theta}) \end{matrix} \right) \right) \quad (1)$$

with covariance vector $\boldsymbol{\theta}$. A vector of n measurements \mathbf{y} is modeled by a $n \times p$ dense matrix \mathbf{X} of fixed effects and their p regression coefficients $\boldsymbol{\beta}$, an $n \times (m q)$ block-diagonal sparse matrix \mathbf{U} of random effects and their $(m q)$ regression coefficients $\boldsymbol{\gamma}$ and an additive error term $\boldsymbol{\epsilon}$. In our application, m corresponds to the number of units (e.g., subjects) included in the study, each with n_i time series measurement, i.e., $n = \sum_{i=1}^m n_i$. Dropping the random effects term

$\mathbf{U}\boldsymbol{\gamma}$ leads to a linear model. Using $\mathbf{V}(\boldsymbol{\theta}) = \mathbf{U} \mathbf{G}(\boldsymbol{\theta}) \mathbf{U}^T + \mathbf{R}(\boldsymbol{\theta})$, the fixed effects $\boldsymbol{\beta}$ and the random effects $\boldsymbol{\gamma}$ are estimated by:

$$\hat{\boldsymbol{\beta}} = \left(\mathbf{x}^T \mathbf{v}(\boldsymbol{\theta})^{-1} \mathbf{x} \right)^{-1} \mathbf{x}^T \mathbf{v}(\boldsymbol{\theta})^{-1} \mathbf{y} \quad \text{and} \quad \hat{\boldsymbol{\gamma}} = \mathbf{G} \hat{\boldsymbol{\beta}}^T \mathbf{v}(\boldsymbol{\theta})^{-1} \left(\mathbf{y} - \mathbf{x} \hat{\boldsymbol{\beta}} \right). \quad (2)$$

The covariance vector is typically estimated using Restricted Maximum Likelihood (REML) by:

$$\hat{\boldsymbol{\theta}} = \arg \max \left(l_p(\boldsymbol{\theta}) - \frac{1}{2} \ln |\mathbf{X}^T \mathbf{V}(\boldsymbol{\theta})^{-1} \mathbf{X}| \right) \quad (3)$$

For the estimation of the model parameters $\boldsymbol{\beta}$, $\boldsymbol{\gamma}_i$ and inference on $\boldsymbol{\beta}$, refer to (Halekoh and Hojsgaard, 2014; Kenward and Roger, 1997; Laird et al., 1987). In order to make the problem identifiable, we make the simplifying assumptions $\boldsymbol{\gamma} \sim N_q(0, \mathbf{D})$ and $\boldsymbol{\epsilon} \sim N_n(0, \sigma^2 \mathbf{I})$ so that the covariance vector $\boldsymbol{\theta}$ has $s = q(q+1)/2 + 1$ parameters. Note that the conditions $n \geq q + mq + s$ and $n_i \geq q$ pose an upper limit on the number of fixed and random regressors p, q .

In our application, \mathbf{y} corresponds to a vector of n voxel-wise measures collected at the brain regions of interest in the study sample. The matrix \mathbf{X} contains p regressors with group-related information (e.g., disease status, sex) and subject-level information (e.g., age). Each sub-matrix \mathbf{U}_i includes information about longitudinal data of subject i (e.g., the time interval between examinations). As a result, we obtain voxel-wise estimates of the regression coefficients $\hat{\boldsymbol{\beta}}$ and their significance levels $\hat{\mathbf{p}}$ are compiled in spatial parameter maps. These parameters correspond to sample-level effects (e.g., WM integrity as a function of aging), and group-level effects (e.g., differences in WM integrity between patients and healthy controls). In addition, we obtain voxel- and subject-wise estimates of regression coefficients $\boldsymbol{\gamma}_i$ that provide local and individual information about WM integrity, relative to the sample average.

2.3. Subjects

This work includes all subjects in the ADNI Go and ADNI 2 studies for which two or more diffusion-weighted MRI scans were available. Besides the diffusion-weighted data set, we also included T1-weighted MR images acquired in the same session. After finding and removing incomplete and low-quality data sets, 177 subjects remained (69 females, 108 males, aged between 48.7 and 90.9 years, mean 74.6 years). Written informed consent was obtained for participation in these studies, approved by the institutional review board at each of the 15 participating centers. A total of 756 examinations were performed between June 2010 and January 2016, corresponding to 2–6 time series examinations per subject. Most typically, intervals between exams were 3 months, 6 months, followed by yearly intervals, although intervals varied considerably. The total observation per included subject ranged between 20 and 1280 days. In addition to the MR images, demographic data (e.g., age, weight, gender) and cognitive scores were collected. At time of enrollment, subjects were classified to 5 clinical groups CN: cognitively normal ($n = 43$); EMCI: “early” mild cognitive impairment ($n = 58$); LMCI: “late” MCI ($n = 33$); SMC: severe memory complaint ($n = 7$); AD: Alzheimer’s disease ($n = 36$). These categories were defined as follow (see ADNI General Procedure Manual, 2016, p.27): CN subjects were (a) free of memory complaints, (b) showed normal memory function in the Logical Memory II subscale from the Wechsler Memory Scale, (c) had an MMSE score at or above 24, and (d) had a clinical dementia rating (CDR) of 0. The classification of AD was based on: (a) memory complaints, (b) abnormal memory function in the Wechsler test, (c) a MMSE score at or below 24, and (d) a dementia rating (CDR) of 0.5 or greater. Subjects classified as any of the MCI groups ranged between these extremes, where EMCI subjects had a better overall result in the memory test than LMCI subjects. Age and gender did not significantly differ between

groups ($p > 0.05$). Results of clinical examinations and diagnostic labels were sampled until September 2016. Of the 98 MCI patients included here, 30 (30.6%) had their diagnosis revised: 26 (26.5%) converted to AD, and 4 reverted to CN.

Data used in the preparation of this article were obtained from the Alzheimer's disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD).

2.4. Imaging protocol

All 15 participating sites were equipped with General Electric Healthcare scanners, models Discovery or Signa. T₁-weighted images were acquired using a 3D IR-FSPGR protocol (TE 3.036 s, TR 7.34 s, TI 400 ms) using a 256 × 256 matrix, 196 sagittal slices, 1.0156 mm in-plane resolution, 1.2 mm slice thickness. Diffusion-weighted images were acquired using an EPI SE protocol (TE 90 ms, TR 9.05 s) using a 256 × 256 matrix, 59 axial slices, 1.37 mm in-plane resolution, 2.7 mm slice thickness, 41 diffusion-weighted volumes at a b-value of 1000 s/mm², 5 isotropic volumes. For further details, see ([ADNI MRI Scanner Protocols, 2016](#)).

2.5. Image analysis

The first sequence of image processing steps aimed at generating a study-specific anatomical template from T₁-weighted imaging data: (A1) T₁-weighted imaging data in DICOM format were converted into BRIAN format. The first data set of each time series was aligned with the stereotactic coordinate system ([Kruggel and von Cramon, 1999a](#)) and interpolated to an isotropic voxel size of 1 mm using a fourth-order b-spline method. Subsequently, the rest of the data sets were aligned with the first one by linear registration. Quality control parameters (e.g., signal-to-noise, contrast-to-noise, image acuity) were computed for all aligned images. Data sets with quality measures in the lowest 10% range were visually assessed, and replaced by alternate scans. (A2) All data sets were registered with the ICBM 2009c template ([Fonov et al., 2009](#)) using non-linear registration ([Vercauteren et al., 2009](#)). All registered head images were averaged, correcting for the mean intensity. The brain was extracted from the average to yield the initial brain template. (A3) A mask of the intracranial volume was generated from each data set by a registration approach and used to remove the outer hulls of the brain ([Hentschel and Kruggel, 2004](#)). A block-wise local intensity-based segmentation was used to correct for global intensity inhomogeneities. (A4) All intensity-corrected brain images were non-linearly registered with the initial template, and averaged to yield the study-specific brain template. Importantly, the non-linear deformation field was saved for the transformation of the diffusion-weighted data.

Diffusion-weighted imaging data were processed by the following pipeline: (D1) Scan data in DICOM format were converted into BRIAN format. Image volumes corresponding to all gradient directions were corrected for eddy-current artifacts and registered with the gradient-free (T₂)-weighted image volume using affine registration and normalized mutual information (NMI) as image similarity metric ([Maes et al., 1997](#)). (D2) Diffusion tensors were computed by a non-linear procedure including anisotropic noise filtering ([Fillard et al., 2007](#)) and converted into scalar images of fractional anisotropy (FA), radial and mean diffusivity (RD, MD) ([Basser and Pierpaoli, 1996](#)) (D3) The gradient-free

images were linearly registered with the aligned T₁-weighted image (step A3) that was acquired at the same examination date as the diffusion-weighted scan using NMI as similarity metric. The obtained transformation parameters were applied to the scalar images. (D4) The subject- and time-point specific non-linear deformation fields (step A4) were used to transform all FA, RD, MD, T₂ images into stereotactic space, smoothed by a Gaussian filter ($\sigma = 2$, FWHM of 4.7 mm), and masked against the study-specific brain template (step A4).

All four image series (T₂, FA, RD, MD) were analyzed by LMEM models, using a $n \times p$ matrix of study-wide and a $n \times q$ matrix of subject-specific covariates. Resulting voxel-wise estimates for the p regression parameters β_i , and their corresponding significance levels were compiled as p volumetric parameter images. In order to correct for multiple comparisons, we either assessed supra-threshold clusters in z-score images ([Friston et al., 1993](#)), or corrected significance levels based on a permutation test ([Benjamini and Hochberg, 1995](#)). Note that the computation was restricted to a brain tissue (GM and WM) mask segmented from our study-specific template (A4).

Image processing was performed on a 30-node computer cluster equipped with AMD 64 two-core CPUs, 4 GB of memory, running under the Debian 8/Linux 3.16 operating system, using the BRIAN image analysis environment ([Kruggel, 2016](#)). We refer to "VBM framework" here as a variant of the techniques described in ([Ashburner and Friston, 2000](#)), implemented in efficient compiled code and more recent image processing techniques. For performing logistic regression, principal component analysis (PCA), and receiver-operating characteristics (ROC), we used the R system ([Hornik, 2014](#)). Neuroanatomical labels were addressed to GM structures and WM fiber bundles via coordinates in standardized space by consulting a neuroanatomical atlas ([Cho, 2010](#)).

3. Results

Mixed effects models allow differentiating between population- and subject-level effects which is necessary for an individual risk assessment in neurodegeneration. First, we describe the population- and disease-related influences on WM degeneration. Next, we derive a subject-level measure that captures aspects of the individual aging process. Finally, we demonstrate how all imaging information can be integrated into a simple classifier that allows distinguishing between healthy controls and subjects with AD at a high level of accuracy.

3.1. Determinants of healthy and pathological aging in WM

We considered a LMEM with the following fixed covariates: age at the time of each examination (AGE), gender (GEN), clinical group (GRP), and brain volume (BRV):

$$y = \beta_0 + \beta_1 AGE + \beta_2 GEN + \beta_3 GRP + \beta_4 BRV + \gamma_0 + \gamma_1 AGE$$

Because individual brain data were mapped into a common space, brain volume is included here as a nuisance regressor.

3.1.1. Age-related effects

To ease the understanding of the spatial continuity of results for age-related fixed effects, we did not threshold the z-score maps. [Fig. 1](#) shows un-thresholded z-score maps (positive range from 0 = red to 8 = white, negative range from 0 = green to -8 = magenta), overlaid onto the study-specific anatomical template. [Table 1](#) collects the location, Talairach coordinates, age-related coefficients β for measures FA, RD, MD, and T₂, their standard deviation, and significance (expressed as z-score) for selected locations.




Fig. 1. Influence of aging on WM, as shown by un-thresholded z-score maps determined from fractional anisotropy (FA), radial diffusivity (RD), mean diffusivity (MD), and T₂ intensity (T2). Positive z-scores range from 0 (red) to 8 (white), negative z-scores from 0 (green) to -8 (magenta). A general pattern of age-related FA decrease, RD, MD and T2 increase is found in most WM compartments. Besides, a second pattern of FA increase and a moderate RD, MD and T2 increase is found in cortical GM and basal ganglia as well as some WM areas. For detail information from selected voxels, refer to Table 1. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

We note:

- There was a generalized age-related decrease of FA in the WM, most nuanced in the ventral portions of both frontal lobes, and rostral-to-medial portions of the corpus callosum. These areas showed the strongest age-related increase of RD, MD, and T2 (pattern 1).
- Conversely, a strong age-related increase of FA, with a moderate decrease in RD, MD, and T2 was found in the GM, most prominently in insula, basal ganglia, and the cingulate gyrus (pattern 2).

nently, in insula, basal ganglia, and the cingulate gyrus (pattern 2).

Several studies have assessed the effects of aging onto WM structures of the human brain (for reviews see Madden et al., 2012; Sullivan and Pfefferbaum, 2006). A general trend across many investigations points to a decrease in FA and an increase in RD and MD with increasing age in adults (pattern 1), corresponding to a decline in WM composition and integrity, with de-myelination

Table 1

Age-dependency of WM and GM measures (FA, RD, MD, T2) at selected locations corresponding to Fig. 1. Tabulated are Talairach coordinates, β (AGE), the relative age-related change (in%) with respect to the intercept, the standard deviation of the β estimate, and the z-score. Units for β are given as [1/year of age] (FA, RD, MD), and [arbitrary intensity unit/year of age] (T2). Note that locations in the putamen and insula correspond to pattern 2, and the others to pattern 1.

Location	Coordinates			Meas	β	% Change	Std.dev	z-score
Fronto-basal WM left	-20	49	9	FA	-4.83E-03	-1.37E+00	7.41E-04	-6.53
	-20	49	9	RD	5.74E-03	8.23E-01	8.97E-04	6.40
	-20	49	9	MD	2.78E-03	3.22E-01	7.69E-04	3.62
	-20	49	9	T2	2.03E+01	1.07E+00	3.66E+00	5.55
Fronto-basal WM right	20	49	9	FA	-4.71E-03	-1.41E+00	7.79E-04	-6.05
	20	49	9	RD	5.61E-03	7.82E-01	9.64E-04	5.82
	20	49	9	MD	3.03E-03	3.45E-01	8.18E-04	3.70
	20	49	9	T2	1.85E+01	9.42E-01	3.94E+00	4.70
Temporo-medial WM left	-41	12	-26	FA	-1.64E-03	-4.62E-01	7.41E-04	-2.21
	-41	12	-26	RD	4.95E-03	7.17E-01	1.35E-03	3.66
	-41	12	-26	MD	4.25E-03	4.90E-01	1.30E-03	3.26
	-41	12	-26	T2	1.94E+01	1.05E+00	3.33E+00	5.85
Temporo-medial WM right	41	12	-26	FA	-1.43E-03	-4.15E-01	8.79E-04	-1.63
	41	12	-26	RD	3.22E-03	4.63E-01	1.06E-03	3.04
	41	12	-26	MD	2.77E-03	3.21E-01	9.86E-04	2.82
	41	12	-26	T2	2.29E+01	1.19E+00	3.73E+00	6.14
Ant. corpus callosum left	-15	1	34	FA	-5.93E-03	-1.66E+00	1.11E-03	-5.32
	-15	1	34	RD	2.04E-02	1.30E+00	5.06E-03	4.04
	-15	1	34	MD	1.78E-02	9.44E-01	4.73E-03	3.76
	-15	1	34	T2	2.31E+01	9.71E-01	7.78E+00	2.97
Ant. corpus callosum right	15	1	34	FA	-4.39E-03	-1.53E+00	9.22E-04	-4.77
	15	1	34	RD	1.76E-02	1.17E+00	4.78E-03	3.70
	15	1	34	MD	1.63E-02	9.39E-01	4.72E-03	3.46
	15	1	34	T2	1.99E+01	7.95E-01	9.67E+00	2.06
Lat. putamen left	-30	17	0	FA	2.38E-03	9.01E-01	7.47E-04	3.19
	-30	17	0	RD	-6.52E-04	-9.42E-02	1.03E-03	-0.63
	-30	17	0	MD	6.13E-04	7.59E-02	9.17E-04	0.67
	-30	17	0	T2	1.10E+01	6.66E-01	3.28E+00	3.35
Lat. putamen right	30	17	0	FA	7.54E-04	2.38E-01	6.52E-04	1.16
	30	17	0	RD	1.45E-03	2.19E-01	8.69E-04	1.68
	30	17	0	MD	2.09E-03	2.61E-01	8.07E-04	2.59
	30	17	0	T2	1.30E+01	7.32E-01	3.58E+00	3.64
Int. capsule post. limb left	-22	-7	-4	FA	-9.87E-04	-1.24E-01	4.20E-04	-2.35
	-22	-7	-4	RD	9.01E-04	3.14E-01	5.06E-04	1.78
	-22	-7	-4	MD	-3.65E-05	-5.13E-03	4.51E-04	-0.08
	-22	-7	-4	T2	2.37E+00	1.35E-01	3.12E+00	0.76
Int. capsule post. limb right	22	-7	-4	FA	-1.35E-03	-1.99E-01	7.23E-04	-1.88
	22	-7	-4	RD	1.85E-03	4.91E-01	6.69E-04	2.77
	22	-7	-4	MD	1.18E-03	1.68E-01	5.00E-04	2.38
	22	-7	-4	T2	3.28E+00	1.84E-01	3.15E+00	1.04
Insular GM left	-40	18	9	FA	7.63E-04	7.00E-01	4.33E-04	1.76
	-40	18	9	RD	1.70E-02	9.47E-01	5.36E-03	3.18
	-40	18	9	MD	1.82E-02	9.51E-01	6.08E-03	3.00
	-40	18	9	T2	3.94E+01	9.68E-01	1.06E+01	3.71
Insular GM right	40	18	9	FA	6.90E-04	5.65E-01	4.82E-04	1.43
	40	18	9	RD	1.73E-02	1.10E+00	5.16E-03	3.36
	40	18	9	MD	1.91E-02	1.14E+00	5.67E-03	3.37
	40	18	9	T2	3.06E+01	7.73E-01	1.12E+01	2.73

as a leading factor (Madden et al., 2012). This pattern is not homogeneous throughout the brain. Besides pattern 1, a strong increase in FA, with a moderate decrease in RD and MD (pattern 2) was found in some GM structures (insula, putamen, pallidum, and the cingulate gyrus). The mechanisms suggested behind this pattern include gliosis, tissue compaction, increased iron deposits (Pfefferbaum et al., 2010; Wang et al., 2010). We prefer the interpretation of a degenerative cytotoxic edema in GM (Lin et al., 2016), because this explanation matches well with the overall occurrence of the affected regions.

3.1.2. Gender-related effects

We show thresholded z-score maps in Fig. 2 (positive range from 3 = red to 8 = white, negative range from -3 = green to -8 = magenta), overlaid onto the study-specific anatomical template. Only regions are shown that were confirmed as significantly different after correction for multiple comparison by controlling the family-wise error rate (Friston et al., 1993), given a cluster selec-

tion threshold of $p < 0.01$. Table 2 collects the location, Talairach coordinates, supra-threshold cluster size (in mm^3), peak and mean z-scores for significantly different regions.

We note:

- Females had significantly higher FA, lower MD and RD in the splenium of the corpus callosum, the inferior fronto-occipital tract on both sides, the superior cerebellar peduncle, nigro-striatal pathways, and in WM of the rostral cerebellum. This pattern is, most likely, due to the larger density and smaller diameter of fiber connections in females.
- Females also had lower FA, higher RD and MD in cortico-fugal fibers and in WM of the caudal cerebellum on both sides. In addition, females had a significantly lower FA and higher T2 in the ventral pallidum, the nucleus accumbens, and its mid- and forebrain connections on both sides. These findings point towards a larger fraction of extra-cellular water in these regions, although the neuroanatomical basis is unclear.




Fig. 2. Differences between males and females, as determined from fractional anisotropy (FA), radial diffusivity (RD), mean diffusivity (MD), and T_2 intensity (T2). Shown are thresholded z-score maps, with positive z-scores ranging from 3 (red) to 8 (white), negative z-scores from -3 (green) to -8 (magenta). Regions shown are corrected for multiple comparison by controlling the family-wise error rate. For detail information of these regions, refer to Table 2. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

While sexual dimorphism in grey matter is well described, relatively little focus has been given to white matter (Hsu et al., 2008; Kovalev et al., 2003), until recently where substantial differences have been described (Ingalhalikar et al., 2014; Kanaan et al., 2012, 2014). Yet, converging results on specific brain regions and the sign of the difference are still missing. Qualitatively, we find a match between our maps and those published by Inano et al. (2011), with the sign reversed, that is, we found a higher FA in females in the splenium of the corpus callosum, in agreement with some (Ingalhalikar et al., 2014; Kanaan et al., 2012, 2014) but not Inano

et al. (2011). Likewise, we found a higher FA in females in the superior cerebellar peduncle and WM in the anterior cerebellum, which was not significant in previous publications (Kanaan et al., 2012, 2014). In addition, females had a significantly lower FA and higher T2 in the globus pallidus, the nucleus accumbens, and its mid- and forebrain WM connections on both sides. This may have been un-noticed before because most other studies used tract-based statistics for analysis, and these regions lie outside the tract atlas. In addition, our population consists of elderly subjects only,

Table 2

Gender-related effects [F-M] on WM and GM measures (FA, RD, MD, T2) at significant regions corresponding to Fig. 2. Tabulated are Talairach coordinates, region size (in mm³), peak and mean z-score of the region. Regions were found by treating the z-score map with a threshold of absolute 3.1 (corresponding to p < 0.001), and assessing the connected regions for significance using the cluster extent (p < 0.01). In addition, regions at the boundary of the imaged domain were excluded.

Meas.	Location	Coordinates			Size	z peak	z mean
FA	Cingulate gyrus left	-6	-32	29	2643	4.916	3.535
	Int. capsule post limb left	-18	-17	5	2086	5.569	3.845
	Int. capsule post limb right	10	-20	17	1434	4.807	3.603
	Middle temporal lobe WM left	-35	-7	-4	1122	5.388	3.642
	Ant. corpus callosum left	-23	28	-5	1095	-5.714	-3.716
	Post. corpus callosum bilat.	-9	-40	16	1999	-5.154	-3.630
	Medial frontal cortex BA 32 bilat.	-2	29	2	1999	-5.573	-3.715
	Post. insula left	-39	-15	22	2114	-5.061	-3.590
	Pallidum right	19	-8	2	4288	-5.960	-3.857
	Pallidum left	-22	-9	0	5247	-5.945	-3.963
	Cerebellum ant. lobe left	-17	-51	-23	1746	5.695	3.744
	Middle Corpus callosum left	-14	-27	25	2845	4.745	3.553
RD	Middle Corpus callosum right	16	-37	24	1169	4.663	3.414
	Post. Corpus callosum bilat.	-1	-39	9	1323	5.897	3.800
	Thalamus fornix caudate nucleus bilat.	-6	-17	3	17948	-6.695	-3.877
	Temporal stem left	-40	-17	-5	1578	-5.069	-3.649
	Cerebellum ant. lobe left	-4	-60	-10	1481	-6.103	-3.454
	Medial temporal lobe right	21	-18	-15	1185	-6.316	-3.616
	Middle Corpus callosum left	-15	-28	25	2468	4.775	3.476
	Post. Corpus callosum bilat.	-1	-39	9	1368	6.248	3.815
	Precuneus left	-4	-65	54	1001	-4.456	-3.488
	Thalamus fornix caudate nucleus bilat.	-6	-17	4	19463	-6.690	-3.865
	Thalamo-cerebellar tract left	-9	-8	-9	2108	5.854	3.806
	Temporal stem left	-38	-13	-4	2295	-5.049	-3.662
MD	Cerebellum ant. lobe left	-6	-58	-14	2370	-4.868	-3.557
	Sup. temporal gyrus WM left	-33	9	-21	1121	-4.574	-3.483
	Medial temporal lobe right	21	-18	-16	1085	-6.681	-3.632
	Basal putamen and pallidum right	20	2	-3	2872	6.417	3.861
	Basal putamen and pallidum left	-18	1	-5	4418	6.591	4.046

while others are based on a broad age range of adults. A thorough assessment of sex-related differences is a subject for future work.

3.1.3. Disease-related effects of AD vs. healthy controls

As for the age-related effects, we did not threshold the z-score maps, to ease the understanding of the spatial continuity of results. Fig. 3 shows un-thresholded z-score maps (positive range from 0 = red to 8 = white, negative range from 0 = green to -8 = magenta), overlaid onto the study-specific anatomical template. Table 3 collects the location, Talairach coordinates, age-related coefficients β for measures FA, RD, MD, and T2, their standard deviation, and significance (expressed as z-score) for selected locations.

We note:

- The main effect was a strong, bilateral disease-related increase of RD and MD in the corpus callosum and hippocampus with a barely significant decrease in FA and increase in T2 (pattern 3).
- A less prominent, disease-related increase of FA and T2, without significant changes in RD and MD was seen in cortico-fugal fibers associated with the pyramidal tract and corona radiata at the level of the supra-ventricular WM, predominant on the left side (pattern 4).

The disease-related pattern 3 parallels previous work (see Chua et al. (2008) for a review). These changes are best explained by a disease-related increase in extra-cellular water, likely due to vasogenic edema (Lin et al., 2016). Regions with the strongest disease-related differences are found bilaterally in the ventro-medial temporal lobe, and in posterior sections of the corpus callosum. Recently, Douaud et al. (2011) reported regions of increased FA in the centrum semiovale which is reproduced in similar extent and location here as pattern 4. We find that this pattern is quite extensive, albeit at a lower significance than pattern 3. As indicated by Bennett et al. (2010) and Douaud et al. (2011), we hypothesize that in those regions with crossing fiber

compartments, one degenerates slower than other(s). Our results are in agreement with the fact that the sensorimotor cortical GM and descending cortico-spinal tract remain relatively intact in AD (Scheltens et al., 1995).

3.2. Measures of individual aging in WM

This was possible as in our mixed model the model (Section 3.1), age is included as both a population-level effect β_1 and as a subject-level effect γ_1 . Thus, individual differences in an image metric are explained as $\Delta y = \gamma_0 + \gamma_1 \text{AGE}$, obtained from the time-series measurements in the particular subject. Let us consider the hypothesis that this difference is due to an unobserved individual difference in the aging process, termed as ΔAGE :

$$\Delta \text{AGE} = \frac{1}{\beta_1} (\beta_4 (\overline{\text{BRV}} - \overline{\text{BRV}}) + \gamma_0 + \gamma_1 \overline{\text{AGE}}),$$

where bars denote subject-wise means. Higher (positive) values indicate that tissue in this voxel aged more than the sample average, while lower (negative) values indicate that tissue in this voxel is less affected by aging. We restricted the computation of ΔAGE to those voxels in which age-related changes are significant ($p < 0.05$, as determined for β_1). Empirical distributions of ΔAGE pass tests for uni-modality (Johnson and Rogers, 1951), indicating that there is a single process generating the data. However, distributions have "heavy tails" on both sides, compared to a Gaussian distribution.

Next, we averaged results across all voxels of a subject. Thus, ΔAGE is now used as a subject-wise measure. The resulting measures, as computed independently from T2 intensities and DTI parameters FA, RD, MD show a high correlation, and a slope close to 1 (for T2, around 0.5), (Table 1). Hence, ΔAGE captures essentially the same biophysical properties when computed from FA, RD, and MD data, and similar properties when computed from T2-weighted data (Table 4).




Fig. 3. Difference between AD patients and healthy controls, as determined from fractional anisotropy (FA), radial diffusivity (RD), mean diffusivity (MD), and T₂ intensity (T2). Shown are un-thresholded z-score maps, with positive z-scores ranging from 0 (red) to 8 (white), negative z-scores from 0 (green) to -8 (magenta). For detail information from selected voxels, refer to Table 3. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

We then performed a linear regression to compute the relationship between ΔAGE and the demographic and clinical data of each subject. Variables AGE, GEN, and brain volume did not significantly influence ΔAGE , confirming that our procedures successfully parceled out these covariates. However, the clinical groups AD (+3.82, $p=0.0005$), EMCI (+3.15, $p=0.0014$) and LMCI (+2.99, $p=0.0081$) differed significantly in their ΔAGE from healthy controls and subjects with severe memory complaints, although this model explains only 8.4% of the variance. Likewise, the MMSE scores were correlated with ΔAGE (-0.345 , $p=0.00355$), suggesting that the measure ΔAGE separates aspects of individual aging from the general (population-level) aging process.

Finally, we studied how the mixed-effects modeling helps estimate a “prototypical” aging function from empirical data. We selected the first (FA, RD, MD, T2) data set from each subject, and averaged measures across all voxels in which a significant age-dependency was found ($p<0.05$). A plot of FA vs. subject age (Fig. 4, top left, red circles) shows a clear age-dependent trend with a considerable inter-subject variability. Adjusting a subject's real age by the estimated individual difference of the aging process, ΔAGE , reduces the inter-individual variance (shown as black dots), i.e., measurements represented as red circles are shifted horizontally by the correction to the black dots. For the age range in this study, the dependence of a measured parameter can be approximated

Table 3

Disease-related effects [AD-NM] on WM and GM measures (FA, RD, MD, T2) at selected locations corresponding to Fig. 3. Tabulated are Talairach coordinates, β (AD-NM), the relative disease-related difference (in%) with respect to the grand mean, the standard deviation of the β estimate, and the z-score. Units for β are given as [1/year of age] (FA, RD, MD), and [arbitrary intensity unit/year of age] (T2). Note that the location in the corona radiata corresponds to pattern 4, and the others to pattern 3.

Location	Coordinates			Meas.	β	% Diff.	Std.dev	z-score
Fronto-basal WM left	-18	51	7	FA	-6.62E-02	-1.82E+01	1.81E-02	-3.65
	-18	51	7	RD	5.47E-02	8.18E+00	1.83E-02	2.98
	-18	51	7	MD	1.86E-02	2.20E+00	1.57E-02	1.18
	-18	51	7	T2	6.56E+01	3.62E+00	6.88E+01	0.95
Post. corpus callosum left	-17	-32	21	FA	-1.65E-01	-4.12E+01	3.18E-02	-5.2
	-17	-32	21	RD	7.10E-01	4.35E+01	1.35E-01	5.23
	-17	-32	21	MD	6.02E-01	2.90E+01	1.26E-01	4.76
	-17	-32	21	T2	1.74E+03	4.17E+01	3.99E+02	4.36
Post. corpus callosum right	17	-37	17	FA	-1.48E-01	-1.90E+01	3.07E-02	-4.81
	17	-37	17	RD	4.40E-01	1.17E+02	9.81E-02	4.49
	17	-37	17	MD	4.41E-01	5.57E+01	9.02E-02	4.89
	17	-37	17	T2	1.34E+03	3.96E+01	3.67E+02	3.65
Sup. temporal gyrus WM right	54	-15	-7	FA	4.22E-03	3.63E+00	1.27E-02	0.33
	54	-15	-7	RD	1.65E-01	1.53E+01	7.41E-02	2.24
	54	-15	-7	MD	1.74E-01	1.53E+01	7.54E-02	2.32
	54	-15	-7	T2	6.86E+02	1.99E+01	2.05E+02	3.34
Corona radiata left	-28	-6	34	FA	7.90E-02	1.80E+01	1.53E-02	5.15
	-28	-6	34	RD	-3.70E-02	-6.42E+00	1.36E-02	-2.71
	-28	-6	34	MD	1.58E-02	2.03E+00	1.19E-02	1.32
	-28	-6	34	T2	1.31E+01	5.98E-01	7.11E-02	5.18
Temporo-medial WM left	-34	1	-21	FA	-2.88E-02	-2.09E+01	1.28E-02	-2.24
	-34	1	-21	RD	4.61E-01	4.93E+01	7.09E-02	6.50
	-34	1	-21	MD	4.81E-01	4.80E+01	7.59E-02	6.34
	-34	1	-21	T2	9.68E+02	3.44E+01	2.03E+02	4.76
Temporo-medial WM right	30	-6	-21	FA	2.24E-03	1.87E+00	7.83E-03	0.29
	30	-6	-21	RD	6.10E-01	4.83E+01	1.08E-01	5.64
	30	-6	-21	MD	6.50E-01	4.85E+01	1.12E-01	5.77
	30	-6	-21	T2	1.27E+03	3.41E+01	2.51E+02	5.08
Parahippo. gyrus WM left	36	-19	-10	FA	2.95E-02	2.16E+01	1.14E-02	2.57
	36	-19	-10	RD	7.30E-01	3.59E+01	1.39E-01	5.25
	36	-19	-10	MD	8.29E-01	3.76E+01	1.53E-01	5.42
	36	-19	-10	T2	1.10E+03	3.54E+01	2.66E+02	4.12
Parahippo. gyrus WM right	-36	-15	-10	FA	-8.95E-03	-5.29E+00	1.25E-02	-0.71
	-36	-15	-10	RD	5.42E-01	2.48E+01	1.31E-01	4.13
	-36	-15	-10	MD	5.62E-01	2.33E+01	1.45E-01	3.86
	-36	-15	-10	T2	1.54E+03	4.18E+01	2.86E+02	5.39

Table 4

Correlation (left) and slope (right) of the proposed individual difference in aging (AGE), as computed from FA, RD, MD and T2 data. The high correlation and a slope close to 1 suggests that essentially the same (biophysical) properties are captured.

	Correlation			Slope		
	RD	MD	T2	RD	MD	T2
FA	0.744	0.817	0.366	0.941	1.004	0.404
RD	1	0.985	0.385	1	0.958	0.538
MD		1	0.415		1	0.562

by a linear relationship (Fig. 4; FA: -0.025/year, $R^2 = 0.92$; RD: +0.0094/year, $R^2 = 0.84$; RD: +0.0094/year, $R^2 = 0.85$; T2: +30.1/year, $R^2 = 0.72$, all $p \sim 0$).

Thus, the linear mixed effects model is able to separate the individual from the population-level variance. Adjusting population data by individual factors leads to better population-based models. These findings also confirm that the initial assumption of a linear dependency of these measures on age is warranted.

3.3. Individual image-based diagnosis

To illustrate the diagnostic power of our methods, we have built an image-based classifier to assess the individual risk of converting to AD. We assume that brains of CN subjects follow a "healthy aging" process, and brains of AD patients a "pathological aging", with region- and age-dependent properties as discussed above, and consider their diagnostic label as true and independent of time. We use this diagnostic information as "ground truth" to build a classifier that distinguishes healthy from pathological aging. For the

brains of the MCI patients in our sample, we assume that their aging process falls into the domain spanned by the two extremes above. To assess the individual risk of converting to AD, we rate their aging process using our image-based classifier.

To describe the individual properties of aging tissue in a voxel, we used the intercept at the mean sample age ($\beta_0 + \gamma_0 + (\beta_1 + \gamma_1) \text{AGE}$) – to represent the individual state of a tissue property at a normalized age, and the subject-specific age-related slope ($\beta_1 + \gamma_1$) – to represent the individual change of a tissue property per time unit. Both values were computed for each measure (FA, RD, MD, T2), yielding a vector of eight values per voxel. We sampled voxel-wise properties from a region-of-interest in the anterior mesial temporal lobe comprised on WM and GM, with a size of 19,500 voxels. WM fibers in this region are affected first by AD, as found from histopathology (Scheltens et al., 1995) and our prior knowledge (Solodkin et al., 2013).

These eight parameters were averaged within a subject, and z-transformed per parameter, yielding 8 normalized measures per subject. Observations from healthy controls and AD patients were




Fig. 4. Age-related changes in FA (top left), RD (top right), MD (below left) and T2 (below right). Red circles corresponds to subject-wise means, black dots to subject-wise means adjusted for the proposed individual difference in the aging process. Note that adjusted data are well modeled by a linear age relationship. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

used to build a classifier using logistic regression, using the diagnostic label as independent, and the subject-wise measures as dependent variables. Predictions from the model have a high discriminative power of 0.991, as assessed by the “area under the curve” (AUC) of a receiver-operating characteristics (ROC) curve. A repeated random sub-sampling cross-validation with a 20% test set yielded a correct prediction rate of 95.4% (95% CI: 0.90–1.0). Applying this classifier to all groups, the following fractions were classified as pathological: AD: 97.2% (35/36); EMCI: 15.5% (9/58); LMCI: 42.8% (14/33); CN: 4.6% (1/22); SMC: 14.3% (1/7) (Fig. 5). Within the observation time frame, 30/91 MCI patients had their diagnosis revised. Of the 23 MCI patients addressed to the pathological domain, 21 (91.3%) converted to AD. Of the 68 MCI patients addressed to the healthy domain, four (5.9%) reverted to CN, and five (7.4%) converted to AD. Classifiers for the distinction of LMCI vs. AD yielded a discriminative power of 0.943, for EMCI vs. AD: 0.833.

The voxels that discriminate best between healthy controls and AD patients were found in over-projection with white matter fiber structures of the hippocampus and parahippocampal regions, e.g., the alveus and the parahippocampal white matter containing the perforant pathway (Fig. 6). Somewhat surprisingly, the optic tract on both sides was also found as discriminatory.

A more parsimonious classifier can be constructed by replacing the z-transformation above with a Principal Component Analysis (PCA), yielding a space spanned by linear combinations of the original eight parameters, with dimensions sorted by their relative importance (i.e., their contribution to the overall variance). We mapped our subject-wise observations into this space, and perform the logistic regression. Here, we can select the dimension(s) that




Fig. 5. Evaluation of individual “health scores” in a region-of-interest in the anterior mesial temporal lobe. Each dot corresponds to a subject average, color-coded by clinical group (AD: black; EMCI: red; LMCI: green; CN: blue; SMC: light blue). A simple linear classifier based on PCA-projected data yields a very high predictive power of 0.991 for distinguishing AD from healthy controls. Note that some MCI patients are clearly mapped into the pathological domain. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

have the highest discriminatory power. Using just one dimension (or regressor), we still found a high predictive power of 0.952 (AUC).

Any other ROI can be devised to build a classifier. A more data-driven approach may start from the disease-related z-maps




Fig. 6. Voxels that discriminate best between healthy controls and AD patients were found in over-projection with white matter fiber structures of the hippocampus and parahippocampus, e.g., the alveus and perforant path. Interestingly, the optic tract on both sides was also found as discriminatory.

obtained in Section 3.1, and select those voxels that most highly discriminate between AD and NC. We defined a region in the middle and posterior corpus callosum, and obtained a classifier with a considerably lower discriminatory power (0.894). A potential explanation is that this region is based on time-independent information (fixed-effects) only, and that dynamic information (from random effects) contributes much to the decision process. More research on the optimization of the region selection is underway.

4. Discussion

In this study, we extended the well-established framework of voxel-based morphometry to the analysis of data from longitudinal imaging studies. We used a large sample of longitudinal DWI images acquired in elderly subjects and demonstrated the high statistical power to pinpoint age-related degeneration patterns in WM, gender-related differences, and patterns related to Alzheimer's disease.

In addition to the assessment of population-level effects, we demonstrate that individualized, subject-level results obtained in a mixed-effects linear model offer additional, neuro-biologically relevant information. In this context we showed how to differentiate general (population-level) aging processes from modulating individual factors.

Pathological signs of WM degeneration obtained in this study are highly discriminative, since a classifier for potential conversion to AD achieved a high predictive power of 0.991, which is among the highest values currently published (Gao et al., 2015; Kohannim et al., 2010; O'Dwyer et al., 2011; Ravetti and Moscato, 2008; Vlassenko et al., 2016; Zu et al., 2015). That is, this classifier provided the membership of some MCI patients into the pathological domain, which are likely candidates for conversion to AD.

To put these contributions into context, it is important to examine the following:

4.1. Mixed-effects modeling of DWI time series data

Technological development is allowing us to move towards precise, individualized medicine. Hence, the logical extension from linear to mixed models offers a distinction between population- to subject-level effects. However, this extension has a price: while regression coefficients in a linear model are directly computed (using the pseudo-inverse of \mathbf{X}), the estimation process in mixed-effects models is inherently iterative, requiring considerably more computational resources. In consequence, most groups so far have used LMEM in relatively small scale analyses on image-derived measures (e.g., Kruggel et al., 2010) or tract-based statistics (Teipel et al., 2007). Recently, an analysis of longitudinal data on neocortical thickness demonstrated the feasibility of this approach (Bernal-Rusiel et al., 2013). That is, an efficient implementation

of the estimation algorithm is essential—and in consequence— we developed an optimized code. Because most operations work on small matrices, porting this code to a mass-parallel graphics processing unit is expected to achieve further gains in speed. However, we found that sample- and group-level results of linear regression were equivalent to those obtained by a mixed-effects model. Thus, a first exploratory approach may use linear models to assess covariates and determine the best composition of \mathbf{X} before moving onto LMEM. Results of a LM can also be used to define regions-of-interest on which are more extensive LMEM is computed.

Note that we considered voxel-wise estimations as spatially independent. Extensions of linear models that take spatial autocorrelations into account have been developed for functional MRI (Katanoda et al., 2002; Kruggel and von Cramon, 1999b). Essentially, a small neighborhood of voxels is considered, and the voxel-wise estimators are “stacked up” to form block-diagonal sparse matrices, connected by a spatial autocorrelation matrix. Because this extension will increase the computation time at least by an order of magnitude, we followed the common practice in voxel-based morphometry and apply either a cluster-level correction (Friston et al., 1993) or a permutation test to control the family-wise error rate (Benjamini and Hochberg, 1995).

Whereas most DWI studies use tract-based statistics to extract image-based metrics early in the analysis process, and conduct inferential analyses at a symbolic (e.g., region) level, our approach is image-based, exploratory, and requires few assumptions. Extending the linear model used in voxel-based morphometry to mixed-effects model is conceptually simple, and allows differentiating between population-, group-level and individual properties.

4.2. WM degeneration as a biomarker for AD

The static and dynamic (time-dependent) image-based measurements can be combined to select regions that are highly discriminative between AD patients and healthy controls. Focusing on the mesial temporal lobe, these include WM structures of the hippocampal formation complex (including the perforant path and alveus), and surprisingly interestingly, the optic tract on both sides. Age- and AD-related changes of the alveus and perforant path are clearly documented by histological (e.g., Arnold et al., 1991; Hyman et al., 1986), and more recently, DWI investigations (Damoiseaux et al., 2009; Fellgiebel and Yakushev, 2011; McEvoy et al., 2009; Rogalski et al., 2009; Salat et al., 2010; Solodkin et al., 2013; Yassa et al., 2010). It was demonstrated that image-based measures are capable of predicting the conversion from MCI to AD (Douaud et al., 2013; Kantarci et al., 2005; Solodkin et al., 2013). Recently, several investigations assessed longitudinal diffusion-weighted data in healthy and pathological aging (Douaud et al., 2011, 2013; Keihaninejad et al., 2013; Kitamura et al., 2013; Sexton et al., 2014; Teipel et al., 2010). Sexton et al. (2014) performed a

tract-based analysis of longitudinal DWI data in subjects with an age range of 20–84 years. They report an overall age-related change of diffusion measures corresponding to our pattern 1, predominantly in the frontal and parietal WM that is accelerating beyond the 5th decade of life, with an approximately linear change in FA, RD and MD. Our approach, using a voxel-wise mixed-effects model, offers a higher spatial resolution, does not bias for specific anatomical regions, and allows assessing individual properties. Douaud et al. (2013) studied a group of 56 amnestic MCI patients, of which some converted to AD, others remained stable over a course of three years. They conclude that predicting progression to AD (based on imaging and CSF protein markers) is possible 2–3 years before clinical symptoms occur.

Our results confirm that DWI-based measures show a high sensitivity for detecting WM degeneration in elderly subjects. Introducing a linear-mixed effects model in the context, we demonstrated that the parameter DAGE, derived from repeated measurement, allows measuring differences in the speed of individual aging w.r.t. the sample. Focusing on the WM of the ventro-mesial temporal lobe, we were able to construct an image-based classifier that predicts the conversion from MCI to AD with a precision of better than 91%, which is comparable to other approaches based on CSF protein biomarkers (Villain et al., 2010), image-based markers (Morris et al., 2009), or a combination of both (Douaud et al., 2013). On an interesting sideline, the optic tract was also found as highly discriminative. While it has been demonstrated that the optic nerve is affected in AD (Hinton et al., 1986; Sadun and Brassi, 1990) we are unaware of any DWI studies that have assessed this structure.

Through this study, we hope to further promote using DWI-based parameters as a biomarker for the early detection of AD. We are aware of a few limitations of this study: (a) we understand that clinical assessments in the ADNI study were not taken at the same time and interval as the image acquisition; (b) the diffusion-weighted imaging protocol may be optimized in terms of spatial resolution, field-of-view, and correction of spatial distortions; (c) replacing the global with an individually defined ROI may enhance the performance of the classifier; (d) while the sensitivity of these measures is repeatedly demonstrated, their specificity (in terms of a differential diagnosis) is unclear. A future study may consider these issues in its design.

To conclude, exchanging the linear model in voxel-based morphometry by a linear-mixed effects model leads to a “natural” extension that allows a statistically rigorous assessment of longitudinal imaging studies while retaining its conceptual simplicity. Separating subject-level effects leads to better sample-level models, as shown for the prototypical WM aging curves here. Relating individual features with respect to a corresponding clinical group (e.g., MCI patients) allows identifying patients with a high risk for converting to AD.

Conflict of interest

The authors have no known or potential conflicts of interest with any people or organizations within 3 years of beginning the submitted work that could inappropriately influence or be perceived to influence their work, including any financial, personal, or other relationships. No conflicts have been identified.

Role of authors

All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. FK programmed the LMEM model and drafted the

manuscript, FM performed the statistical analysis, and AS provided neuroanatomical advice and interpretation.

Acknowledgments

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IX-ICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; MesoScale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

References

- ADNI General Procedure Manual. <http://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf> (Accessed 21 July 2016).
- ADNI MRI Scanner Protocols. <http://adni.loni.usc.edu/methods/documents/mri-protocols/> (Accessed 21 July 2016).
- Amlien, I.K., Fjell, A.M., 2014. Diffusion tensor imaging of white matter degeneration in alzheimer's disease and mild cognitive impairment. *Neuroscience* 276, 206–215.
- Arnold, S.E., Hyman, B.T., Flory, J., Damasio, A.R., van Hoesen, G.W., 1991. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. *Cereb. Cortex* 1, 103–116.
- Ashburner, J., Friston, K.J., 2000. Voxel-based morphometry—the methods. *Neuroimage* 11, 805–821.
- Basser, P.J., Pierpaoli, C., 1996. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. *J. Magn. Reson.* 111, 209–219.
- Beckmann, C.F., Jenkinson, M., Smith, S.M., 2003. General multilevel linear modeling for group analysis in fMRI. *Neuroimage* 20, 1052–1063.
- Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical approach to multiple testing. *J. R. Stat. Soc. Ser. B* 57, 289–300.
- Bennett, I.J., Madden, D.J., Vaidya, C.J., Howard, D.V., Howard, J.H., 2010. Age-related differences in multiple measures of white matter integrity: a diffusion tensor imaging study of healthy aging. *Hum. Brain Mapp.* 31, 378–390.
- Bernal-Rusiel, J.L., Greve, D.N., Reuter, M., Fischl, B., Sabuncu, M.R., 2013. Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models.
- Braskie, M.N., Toga, A.W., Thompson, P.M., 2013. Recent advances in imaging Alzheimer's disease. *J. Alzheimer's Dis.* 33, S313–S327.
- Cho, Z.H., 2010. *7.0 Tesla MRI Brain Atlas*. Springer, New York.
- Chua, T.C., Wen, W., Slavin, M.H., Sachdev, P.S., 2008. Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. *Curr. Opin. Neurol.* 21, 83–92.
- Damoiseaux, J.S., Smith, S.M., Witter, M.P., Sanz-Arigita, E.J., Barkhof, F., Scheltens, P., Stam, C.J., Zarei, M., Rombouts, S.A., 2009. White matter tract integrity in aging and Alzheimer's disease. *Hum. Brain Mapp.* 30, 1051–1059.
- Douaud, G., Jbabdi, S., Behrens, T.E.J., Menke, R.A., Gass, A., Monsch, A.U., Rao, A., Whitcher, B., Kindermann, G., Matthews, P.M., Smith, S., 2011. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. *Neuroimage* 55, 880–890.
- Douaud, G., Menke, R.A.L., Gass, A., Monsch, A.U., Rao, A., Whitcher, B., Zamboni, G., Matthews, P.M., Sollberger, M., Smith, S., 2013. *J. Neurosci.* 33, 2147–2155.

- Driscoll, I., Davatzikos, C., An, Y., Wu, X., Shen, D., Kraut, M., Resnick, S.M., 2009. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. *Neurology* 72, 1906–1913.
- Fellgiebel, A., Yakushev, I., 2011. Diffusion tensor imaging of the hippocampus in MCI and early Alzheimer's disease. *J. Alzheimer's Dis.* 26, 257–262.
- Fillard, P., Pennec, X., Arsigny, V., Ayache, N., 2007. Clinical DT-MRI estimation, smoothing, and fiber tracking with log-euclidean metrics. *IEEE Trans. Med. Imaging* 26, 1476–1482.
- Fonov, V.S., Evans, A.C., McKinstry, R.C., Almlí, C.R., Collins, D.L., 2009. Unbiased non-linear average age-appropriate brain templates from birth to adulthood. *Neuroimage* 47, S102.
- Friston, K.J., Worsley, K.J., Frackowiak, R.S.J., Mazziotta, J.C., Evans, A.C., 1993. Assessing the significance of focal activations using their spatial extent. *Hum. Brain Mapp.* 1, 210–220.
- Galecki, A., Burzykowsli, T., 2013. *Linear Mixed-Effects Models Using R*. Springer, Heidelberg.
- Gao, Y., Wee, C.Y., Kim, M., Giannakopoulos, P., Montandon, M.L., Haller, S., Shen, D., 2015. MCI identification by joint learning on multiple MRI data. In: *Proceedings of the 18th Conference Medical Imaging and Computer-Assisted Intervention*. Springer Heidelberg, pp. 78–85.
- Halekoh, U., Hojsgaard, S., 2014. A Kenward-Roger approximation and parametric boot-strap methods for tests in linear mixed models—the R package pbkrtest. *J. Stat. Softw.* 59, 1–32.
- Hentschel, S., Kruggel, F., 2004. Determination of the intracranial volume: a registration approach. In: Jiang, T. (Ed.), *International Workshop on Medical Imaging and Augmented Reality (MIAR 2004)*, Lecture Notes in Computer Science, vol. 3150. Springer, Berlin, pp. 253–260.
- Hinton, D.R., Sadun, A.A., Blanks, J.C., Miller, C.A., 1986. Optic-nerve degeneration in Alzheimer's disease. *N. Engl. J. Med.* 315, 485–487.
- Hornik, K., 2014. R FAQ. <http://CRAN.R-project.org/doc/FAQ/R-FAQ.html> (Accessed 21 July 2016).
- Hsu, J.L., Leemans, A., Bai, C.H., Lee, C.H., Tsai, Y.F., Chiu, H.C., Chen, W.H., 2008. Gender differences and age-related white matter changes of the human brain: a diffusion tensor imaging study. *Neuroimage* 39, 566–577.
- Huang, H., Fan, X., Weiner, M., Martin-Cook, K., Xiao, G., Davis, J., Devous, M., Rosenberg, R., Diaz-Arrastia, R., 2012. Distinctive disruption patterns of white matter tracts in Alzheimer's disease with full diffusion tensor characterization. *Neurobiol. Aging* 33, 2029–2045.
- Hyman, B.T., van Hoesen, G.W., Kromer, L.J., Damasio, A.R., 1986. Perforant pathway changes and the memory impairment of Alzheimer's disease. *Ann. Neurol.* 20, 472–481.
- Inano, S., Takao, H., Hayashi, N., Abe, O., Ohtomo, K., 2011. Effects of age and gender on white matter integrity. *Am. J. Neuroradiol.* 32, 2103–2109.
- Ingallalikar, M., Smith, A., Parker, D., Satterthwaite, T.D., Elliott, M.A., Ruparel, K., Harkonarson, H., Gur, R.E., Gur, R.C., Verma, R., 2014. Sex differences in the structural connectome of the human brain. *Proc. Natl. Acad. Sci. U. S. A.* 111, 823–828.
- Johnson, N.L., Rogers, C.A., 1951. The moment problem for unimodal distributions. *Ann. Math. Stat.* 22, 433–439.
- Kanaan, R.A., Allin, M., Picchioni, M., Barker, G.J., Daly, E., Shergill, S.S., McGuire, P.K., 2012. Gender differences in white matter microstructure. *PLoS One* 7, e38272.
- Kanaan, R.A., Chaddock, C., Allin, M., Picchioni, M.M., Daly, E., Shergill, S.S., McGuire, P.K., 2014. Gender influence on white matter microstructure: a tract-based spatial statistics analysis. *PLoS One* 9, e91109.
- Kantarci, K., Petersen, R.C., Boeve, B.F., Knopman, D.S., Weigand, S.D., O'Brien, P.C., Shiung, M.M., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Jack, C.R., 2005. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. *Neurology* 64, 902–904.
- Katano, K., Matsuda, Y., Sugishita, M., 2002. A spatio-temporal regression model for the analysis of functional MRI data. *Neuroimage* 17, 1415–1428.
- Keihaninejad, S., Zhang, H., Ryan, N.S., Malone, I.B., Modat, M., Cardoso, H.J., Cash, D.M., Fox, N.C., Ourselin, S., 2013. An unbiased longitudinal analysis framework for tracking white matter changes using diffusion tensor imaging with application to Alzheimer's disease. *Neuroimage* 72, 153–163.
- Kenward, M.G., Roger, J.H., 1997. Small sample inference for fixed effects from restricted maximum likelihood. *Biometrika* 53, 983–997.
- Kitamura, S., Kiuchi, K., Taoka, T., Hashimoto, K., Ueda, S., Yasuno, F., Morikawa, M., Kichikawa, K., Kishimoto, T., 2013. Longitudinal white matter changes in Alzheimer's disease: a tractography-based analysis study. *Brain Res.* 1515, 12–18.
- Kohannim, O., Hua, X., Hibar, D.P., Lee, S., Chou, Y.Y., Toga, A.W., Jack, C.R., Weiner, M.W., Thompson, P.M., 2010. The Alzheimer's Disease Neuroimaging Initiative, Boosting power for clinical trials using classifiers based on multiple biomarkers. *Neurobiol. Aging* 31, 1429–1442.
- Kovalev, V.A., Kruggel, F., von Cramon, D.Y., 2003. Gender and age effects in structural brain asymmetry as measured by MRI texture analysis. *Neuroimage* 19, 895–905.
- Kruggel, F., von Cramon, D.Y., 1999a. Alignment of magnetic-resonance brain data sets with the stereotactic coordinate system. *Med. Image Anal.* 3, 1–11.
- Kruggel, F., von Cramon, D.Y., 1999b. Modeling the hemodynamic response in single-trial functional MRI experiments. *Magn. Reson. Med.* 42, 787–797.
- Kruggel, F., Turner, J., Muftuler, L.T., 2010. Impact of scanner hardware and imaging proto-col on image quality and compartment volume precision in the ADNI cohort. *Neuroimage* 49, 2123–2133.
- Kruggel, F., 2016. The BRIAN system. <http://sip.eng.uci.edu/index.php?page=brian> (Accessed 21 July 2016).
- Laird, N., Lange, N., Stram, D., 1987. Maximum likelihood computations with repeated measures: application of the EM algorithm. *J. Am. Stat. Assoc.* 82, 97–105.
- Lin, M., He, H., Schiffito, G., Zhong, J., 2016. Simulation of changes in diffusion-related to different pathologies at cellular level after traumatic brain injury. *Magn. Reson. Med.* 76, 290–300.
- Lindstrom, M.J., Bates, D.M., 1988. Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. *J. Am. Stat. Assoc.* 83, 1014–1022.
- Liu, F., Suk, H.I., Wee, C.Y., Chen, H., Shen, D., 2013. High-order graph matching based feature selection for Alzheimer's disease identification. In: *Proceedings of the 16th Conference Medical Imaging and Computer-Assisted Intervention*. Springer, Heidelberg, pp. 319–328.
- Madden, D.J., Bennett, I.J., Burzynska, A., Potter, G.G., Chen, N.K., Song, A.W., 2012. Diffusion tensor imaging of cerebral white matter integrity in cognitive aging. *Biochim. Biophys. Acta* 1822, 386–400.
- Maes, F., Maes, A., Collignon, D., Vandermeulen, D., Marchal, A., Suetens, P., 1997. Multi-modality image registration by maximization of mutual information. *IEEE Trans. Med. Imaging* 16, 187–198.
- Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., Hall, W.J., Fisher, S.G., Peterson, D.R., Haley, J.M., Nazar, M.D., Rich, S.A., Berlau, D.J., Peitz, C.B., Tan, M.T., Kawas, C.H., Federoff, H.J., 2014. Plasma phospholipids identify antecedent memory impairment in older adults. *Nat. Med.* 20, 415–418.
- McEvoy, L.K., Fennema-Notestine, C., Roddey, J.C., Hagler, D.J., Holland, D., Karow, D.S., Pung, C.J., Brewer, J.B., Dale, A.M., 2009. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. *Radiology* 251, 195–205.
- McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Demen.* 7, 263–269.
- Molinuevo, J.L., Ripolles, P., Simo, M., Llado, A., Olives, J., Balasa, M., Antonell, A., Rodriguez-Fornells, A., Ramí, L., 2014. White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid b protein 42 levels. *Neurobiol. Aging* 35, 2671–2680.
- Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Holtzman, D.M., Mintun, M.A., 2009. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. *Arch. Neurol.* 66, 1469–1475.
- Nir, T.M., Villalon-Reina, J.E., Prasad, G., Jahanshad, N., Joshi, S.H., Toga, A.W., Bernstein, M.A., Jack Jr., C.R., Weiner, M.W., Thompson, P.M., 2015. Diffusion weighted imaging-based maximum density path analysis and classification of Alzheimer's disease. *Neurobiol. Aging* 36, 5132–5140.
- O'Dwyer, L., Lamberton, F., Bokde, A.L.W., Ewers, M., Faluyi, Y.O., Tanner, C., Mazoyer, B., O'Neill, D., Bartley, M., Collins, D.R., Coughlan, T., Prvulovic, D., Hampel, H., 2011. Using diffusion tensor imaging and mixed-effects models to investigate primary and secondary white matter degeneration in Alzheimer's disease and mild cognitive impairment. *J. Alzheimer's Dis.* 26, 667–682.
- Pfefferbaum, A., Adalsteinsson, E., Rohlfing, T., Sullivan, E.V., 2010. Diffusion tensor imaging of deep gray matter brain structures: effects of age and iron concentration. *Neurobiol. Aging* 31, 482–493.
- Ravetti, M.G., Moscato, P., 2008. Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. *PLoS One* 10, e1371.
- Resnick, S.M., Pham, D.L., Kraut, M.A., Zonderman, A.B., Davatzikos, C., 2003. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. *J. Neurosci.* 23, 3295–3301.
- Rogalski, E.J., Murphy, C.M., deToledo-Morrell, L., Shah, R.C., Moseley, M.E., Bammer, R., Stebbins, G.T., 2009. Changes in parahippocampal white matter integrity in amnestic mild cognitive impairment: a diffusion tensor imaging study. *Behav. Neurol.* 21, 51–61.
- Sadun, A., Brassi, C.J., 1990. Optic nerve damage in Alzheimer's disease. *Ophthalmology* 97, 9–17.
- Salat, D.H., Tuch, D.S., van der Kouwe, A.J.W., Greve, D.N., Pappu, V., Lee, S.Y., Hevelone, N.D., Zaleta, A.K., Growdon, J.H., Corkin, S., Fischl, B., Rosas, H.D., 2010. White matter pathology isolates the hippocampal formation in Alzheimer's disease. *Neurobiol. Aging* 31, 244–256.
- Scheltens, P., Barkhof, D., Leyte, D., Wolters, E.C., Ravid, R., Kamphorst, W., 1995. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. *Neurology* 45, 883–888.
- Schumann, C.M., Bloss, C.S., Barnes, C.C., Wideman, G.M., Carper, R.A., Akshoomoff, A., Pierce, K., Hagler, D., Schork, N., Lord, C., Courchesne, E., 2010. Longitudinal magnetic resonance imaging study of cortical development through early childhood in autism. *J. Neurosci.* 30, 4419–4427.
- Sexton, C.E., Walhovd, K.B., Storsve, A.B., Tamnes, C.K., Westlye, L.T., Johansen-Berg, H., Fjell, A.M., 2014. Accelerated changes in white matter microstructure during aging: a longitudinal diffusion tensor imaging study. *J. Neurosci.* 34, 15425–15436.
- Solodkin, A., Chen, E.E., van Hoesen, G.W., Heimer, L., Shereen, A., Kruggel, F., Mastrianni, J., 2013. In vivo parahippocampal white matter pathology as a

- biomarker of disease progression to Alzheimer's disease.** *J. Comp. Neurol.* **18**, 4300–4317.
- Suk, H.I., Shen, D., 2014. Clustering-induced multi-task learning for AD/MCI classification. In: Proceedings of the 17th Conference Medical Imaging and Computer-Assisted Intervention, Springer, Heidelberg, pp. 393–400.
- Sullivan, E.V., Pfefferbaum, A., 2006. Methodological and conceptual advances in the study of brain-behavior dynamics: a multivariate lifespan perspective. *Neurosci. Biobehav. Rev.* **30**, 749–761.
- Sullivan, E.V., Pfefferbaum, A., 2007. Neuroradiological characterization of normal adult ageing. *Br. J. Radiol.* **80**, S99–S108.
- Teipel, S.J., Stahl, R., Dietrich, O., Schoenberg, S.O., Perneczky, R., Bokde, A.L., Reiser, M.F., Moller, H.J., Hampel, H., 2007. Multivariate network analysis of fiber tract integrity in Alzheimer's disease. *Neuroimage* **34**, 985–995.
- Teipel, S.J., Meindl, T., Wagner, M., Stieltjes, B., Reuter, S., Hauenstein, K.H., Filippi, M., Ernemann, U., Reiser, M.F., Hampel, H., 2010. Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. *J. Alzheimer's Dis.* **22**, 507–522.
- Teipel, S.J., Grothe, M.J., Filippi, M., Fellgiebel, A., Dyrba, M., Frisoni, G.B., Meindl, T., Bokde, A.L.W., Hampel, H., Klöppel, S., Hauenstein, K., 2014. Fractional anisotropy changes in Alzheimer's disease depend on the underlying fiber tract architecture: a multiparametric DTI study using joint independent component analysis. *J. Alzheimer's Dis.* **41**, 69–83, <http://dx.doi.org/10.3233/JAD-131829>.
- Vercauteren, T., Pennec, X., Perchant, A., Ayache, N., 2009. Diffeomorphic demons: efficient non-parametric image registration. *Neuroimage* **49**, S61–S72.
- Villain, N., Fouquet, M., Baron, J.C., Mezenga, F., Landeau, B., de La Sayette, V., Viader, F., Eustache, F., Desgranges, B., Chetelat, G., 2010. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. *Brain* **133**, 3301–3314.
- Vlassenko, A.G., McCue, L., Jasielec, M.S., Su, Y., Gordon, B.A., Xiong, C., Holtzman, D.M., Benzinger, T.L., Morris, J.C., Fagan, A.M., 2016. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. *Ann. Neurol.* **80** (July 11), <http://dx.doi.org/10.1002/ana.24719>.
- Wang, Q., Xu, X., Zhang, M., 2010. Normal aging in the basal ganglia evaluated by eigenvalues of Diffusion Tensor Imaging. *Am. J. Neuroradiol.* **31**, 516–520.
- Wang, T., Shi, F., Jin, Y., Yap, P.T., Wee, C.Y., Zhang, J., Yang, C., Li, X., Xiao, S., Shen, D., 2016. Multilevel deficiency of white matter connectivity networks in Alzheimer's disease: a diffusion MRI study with DTI and HARDI models. *Neural Plas.* **2016**, <http://dx.doi.org/10.1155/2016/2947136>, Article ID 2947136, 14 pages.
- Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C., Harvey, D., Jack, C.R., Jagust, W., Liu, E., Morris, J.C., Petersen, R.C., Saykin, A.J., Schmidt, M.E., Shaw, L., Siuciak, J.A., Soares, H., Toga, A.W., Trojanowski, J.Q., 2012. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. *Alzheimer's Demen.* **8**, S1–S68.
- Yassa, M.A., Muftuler, L.T., Stark, C.E., 2010. Ultrahigh-resolution microstructural diffusion tensor imaging reveals perforant path degradation in aged humans in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 12687–12691.
- Yu, G., Liu, Y., Shen, D., 2016. Graph-guided joint prediction of class label and clinical scores for the Alzheimer's disease. *Brain Struct. Funct.* **221**, 3787–3801.
- Zhan, L., Zhou, J., Wang, Y., Jin, Y., Jahanshad, N., Prasad, G., Nir, T.M., Leonardo, C.D., Ye, J., Thompson, P.M., 2015. Comparison of nine tractography algorithms for detecting abnormal structural brain networks in Alzheimer's disease. *Front. Aging Neurosci.* **7**, 14, <http://dx.doi.org/10.3389/fnagi.2015.00048>.
- Zu, C., Jie, B., Liu, M., Chen, S., Shen, D., 2015. Label-aligned multi-task feature learning for multimodal classification of Alzheimer's disease and mild cognitive impairment. *Brain Imaging and Behavior* **10**, 1148, <http://dx.doi.org/10.1007/s11682-015-9480-7>.